165 related articles for article (PubMed ID: 22702640)
1. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study.
Bar-Oz B; Weber-Schoendorfer C; Berlin M; Clementi M; Di Gianantonio E; de Vries L; De Santis M; Merlob P; Stahl B; Eleftheriou G; Maňáková E; Hubičková-Heringová L; Youngster I; Berkovitch M
Drug Saf; 2012 Jul; 35(7):589-98. PubMed ID: 22702640
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy outcome after gestational exposure to the new macrolides: a prospective multi-center observational study.
Bar-Oz B; Diav-Citrin O; Shechtman S; Tellem R; Arnon J; Francetic I; Berkovitch M; Ornoy A
Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):31-4. PubMed ID: 18760873
[TBL] [Abstract][Full Text] [Related]
3. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study.
Fan H; Gilbert R; O'Callaghan F; Li L
BMJ; 2020 Feb; 368():m331. PubMed ID: 32075790
[TBL] [Abstract][Full Text] [Related]
4. Fetal safety of macrolides.
Bahat Dinur A; Koren G; Matok I; Wiznitzer A; Uziel E; Gorodischer R; Levy A
Antimicrob Agents Chemother; 2013 Jul; 57(7):3307-11. PubMed ID: 23650169
[TBL] [Abstract][Full Text] [Related]
5. Use of macrolides during pregnancy and the risk of birth defects: a population-based study.
Bérard A; Sheehy O; Zhao JP; Nordeng H
Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1241-8. PubMed ID: 26513406
[TBL] [Abstract][Full Text] [Related]
6. First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy.
De Santis M; Di Gianantonio E; Cesari E; Ambrosini G; Straface G; Clementi M
Drug Saf; 2009; 32(3):239-44. PubMed ID: 19338381
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway.
Romøren M; Lindbæk M; Nordeng H
Br J Clin Pharmacol; 2012 Dec; 74(6):1053-62. PubMed ID: 22463376
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy outcomes following maternal macrolide use: A systematic review and meta-analysis.
Keskin-Arslan E; Erol H; Uysal N; Karadas B; Temiz T; Kaplan YC
Reprod Toxicol; 2023 Jan; 115():124-146. PubMed ID: 36549458
[TBL] [Abstract][Full Text] [Related]
9. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis.
Cassina M; Donà M; Di Gianantonio E; Litta P; Clementi M
Hum Reprod Update; 2014; 20(5):656-69. PubMed ID: 24861556
[TBL] [Abstract][Full Text] [Related]
10. Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication?
Auffret M; Bernard-Phalippon N; Dekemp J; Carlier P; Gervoise Boyer M; Vial T; Gautier S
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():188-192. PubMed ID: 27865944
[TBL] [Abstract][Full Text] [Related]
11. In utero exposure to antibiotics and risk of congenital malformations: a population-based study.
Damkier P; Brønniche LMS; Korch-Frandsen JFB; Broe A
Am J Obstet Gynecol; 2019 Dec; 221(6):648.e1-648.e15. PubMed ID: 31260651
[TBL] [Abstract][Full Text] [Related]
12. Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case-control study.
Leke AZ; Dolk H; Loane M; Casson K; Nelen V; Barišić I; Garne E; Rissman A; O'Mahony M; Neville AJ; Pierini A; Bergman JEH; Klungsøyr K; Materna-Kiryluk A; Bielenska AL; Carbonell CC; Addor MC; Tucker D
Reprod Toxicol; 2021 Mar; 100():101-108. PubMed ID: 33454317
[TBL] [Abstract][Full Text] [Related]
13. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
Huybrechts KF; Hernández-Díaz S; Straub L; Gray KJ; Zhu Y; Patorno E; Desai RJ; Mogun H; Bateman BT
JAMA; 2018 Dec; 320(23):2429-2437. PubMed ID: 30561479
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcome after in utero exposure to valproate : evidence of dose relationship in teratogenic effect.
Diav-Citrin O; Shechtman S; Bar-Oz B; Cantrell D; Arnon J; Ornoy A
CNS Drugs; 2008; 22(4):325-34. PubMed ID: 18336060
[TBL] [Abstract][Full Text] [Related]
15. Safety of macrolides during pregnancy.
Lin KJ; Mitchell AA; Yau WP; Louik C; Hernández-Díaz S
Am J Obstet Gynecol; 2013 Mar; 208(3):221.e1-8. PubMed ID: 23254249
[TBL] [Abstract][Full Text] [Related]
16. Prenatal Exposure to Macrolides and Risk of Congenital Malformations: A Meta-Analysis.
Mallah N; Tohidinik HR; Etminan M; Figueiras A; Takkouche B
Drug Saf; 2020 Mar; 43(3):211-221. PubMed ID: 31721138
[TBL] [Abstract][Full Text] [Related]
17. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study.
Diav-Citrin O; Shechtman S; Ornoy S; Arnon J; Schaefer C; Garbis H; Clementi M; Ornoy A
J Clin Psychiatry; 2005 Mar; 66(3):317-22. PubMed ID: 15766297
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study.
Winterfeld U; Allignol A; Panchaud A; Rothuizen LE; Merlob P; Cuppers-Maarschalkerweerd B; Vial T; Stephens S; Clementi M; De Santis M; Pistelli A; Berlin M; Eleftheriou G; Maňáková E; Buclin T
BJOG; 2013 Mar; 120(4):463-71. PubMed ID: 23194157
[TBL] [Abstract][Full Text] [Related]
19. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations.
Charlton RA; Weil JG; Cunnington MC; Ray S; de Vries CS
Drug Saf; 2011 Feb; 34(2):157-71. PubMed ID: 21247222
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid monotherapy in pregnancy and major congenital malformations.
Jentink J; Loane MA; Dolk H; Barisic I; Garne E; Morris JK; de Jong-van den Berg LT;
N Engl J Med; 2010 Jun; 362(23):2185-93. PubMed ID: 20558369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
